This report describes the effects of @entity3446 on plasma lipids, and uses the Framingham risk model to assess the clinical importance of these effects. Lipid data from two large controlled studies of 1295 renal transplant @entity1 were analyzed retrospectively. @entity3446 2 mg/day and 5 mg/day were compared with placebo or @entity500 , and administered concomitantly with @entity230 and @entity205 over 12 months. @entity1007 and @entity2298 occurred in all treatment groups and were maximal at 2-3 months. The @entity3446 groups evidenced higher lipid levels than the controls, but the elevations diminished over time. At 1 year, the @entity1 given @entity3446 2 mg/day had a mean @entity165 level 17 mg/dL greater and a mean @entity412 level 59 mg/dL greater than the controls. Among the @entity1 given @entity3446 5 mg/day, mean @entity165 was 30 mg/dL greater and mean @entity1674 were 103 mg/dL greater than the controls. Treatment with statins and fibrates was effective in reducing @entity165 and @entity412 levels, respectively, in the @entity3446 -treated @entity1 . The Framingham risk model predicted that the 17 mg/dL elevation in @entity165 would increase the incidence of @entity301 ( @entity301 ) by 1.5 new cases per 1000 @entity1 per year and @entity301 death by 0.7 events per 1000 @entity1 per year. Lipid elevations observed in the @entity3446 -treated @entity1 were manageable, improved over time, and responded to lipid-lowering therapy. Based on the Framingham risk model, the @entity301 risks associated with these @entity165 elevations are small compared with the baseline risks of the transplant population.

Effects of XXXX on lipids in renal allograft recipients: an analysis using the Framingham risk model.

@entity1 :: ('9606', 'Species') :: ['patients', 'persons'] @entity2298 :: ('MESH:D015228', 'Disease') :: ['hypertriglyceridemia'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['Hypercholesterolemia'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity301 :: ('MESH:D003327', 'Disease') :: ['CHD', 'coronary heart disease'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus', 'Sirolimus'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity3446 :: (MESH:D020123,Chemical) :: ['sirolimus']
